Some vaginal bacteria may weaken anti-HIV gel: study

June 1, 2017
HIV infecting a human cell. Credit: NIH

Some kinds of vaginal bacteria may interfere with a gel meant to curb the risk of contracting HIV, which infects more than one million women worldwide each year, researchers said Thursday.

The findings in the journal Science were based on a 2010 study of women in South Africa who used the microbicide drug tenofovir, in vaginal gel form, to assess how well it worked at preventing transmission of (HIV).

The drug has shown success in preventing HIV in high-risk men, but studies involving women have been "disappointing," said the report.

A 2010 randomized trial called CAPRISA 004 showed that , applied before and after sex, reduced HIV incidence by 39 percent.

Researchers examined a subset of women who were infected with HIV during the study, even though they used the gel regularly.

Women who became infected with HIV tended to have a dominant bacteria known as Gardnerella vaginalis, which "could rapidly metabolize and break down the active form of the drug," said the report.

Gardnerella vaginalis is associated with a condition known as bacterial vaginosis (BV).

BV is known to increase the risk of HIV because it increases inflammation, disrupts the vaginal wall and impairs wound-healing, and women from sub-Saharan Africa have high prevalence rates of BV, according to background information in the report.

Women with healthier vaginal bacterial compositions—those dominated by the bacteria Lactobacillus—showed three-fold higher protection against HIV than women with different dominant vaginal bacteria compositions.

An accompanying Perspective article in Science pointed out that the research sheds some light on the reasons for the trial's shortcomings, but fails to offer a solution.

Even if women were tested for vaginal , it remains unclear whether the microbiome could be changed to allow for better performance of the gel, since BV returns in nearly 60 percent of women one year after treatment, wrote Susan Tuddenham and Khalil G. Ghanem of the Johns Hopkins University School of Medicine.

In the meantime, the study serves as a reminder that "without a deeper understanding of the structure, function, and dynamics of the vaginal microbiome, successful interventions to optimize it and improve 's health will remain elusive."

Explore further: Vaginal bacteria can trigger recurrent UTIs, study shows

More information: N.R. Klatt el al., "Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women," Science (2017). … 1126/science.aai9383

S. Tuddenham el al., "A microbiome variable in the HIV-prevention equation," Science (2017). … 1126/science.aan6103

Related Stories

Vaginal bacteria can trigger recurrent UTIs, study shows

March 30, 2017
About half of all women will experience urinary tract infections in their lifetimes, and despite treatment, about a quarter will develop recurrent infections within six months of initial infection.

New evidence on why young women in South Africa are at high risk of HIV infection

July 18, 2016
Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, ...

Oral probiotics have no impact on vaginal health in pregnancy

November 1, 2016
(HealthDay)—For pregnant women, probiotics have no effect on vaginal health, according to a study published in the November issue of the American Journal of Obstetrics & Gynecology.

Certain species of vaginal bacteria can increase a woman's susceptibility to HIV

January 10, 2017
Specific bacteria living in the human vagina may play a previously unrecognized role in the sexual transmission of HIV. Ragon Institute researchers, working with young, healthy, South African women, found that individuals ...

Vaginal estriol gel helps women recover after surgery for pelvic organ prolapse

March 29, 2017
Pelvic organ prolapse is estimated to affect up to one-half of all women, causing pain and interfering with sexual function. A new study demonstrates how an ultralow dose of vaginal estriol gel used before and after pelvic ...

Abnormal pap posthysterectomy for 30 percent of HIV+ women

June 14, 2016
(HealthDay)—About one-in-three HIV-infected women with no prehysterectomy history of abnormal Pap results have abnormal vaginal Pap results after hysterectomy, according to a study published in the July issue of Obstetrics ...

Recommended for you

Researchers find new way to defeat HIV latency

March 8, 2018
HIV, the virus that causes AIDS, has a secret life. Though anti-retroviral therapy can reduce its numbers, the virus can hide and avoid both treatments and the body's immune response.

Broadly neutralizing antibody treatment may target viral reservoir in monkeys

March 5, 2018
After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed ...

HIV begins to yield secrets of how it hides in cells

March 2, 2018
UC San Francisco scientists have uncovered new mechanisms by which HIV hides in infected cells, resting in a latent state that evades the body's immune system and prevents antiviral drugs from flushing it out.

HIV exports viral protein in cellular packages

February 15, 2018
HIV may be able to affect cells it can't directly infect by packaging a key protein within the host's cellular mail and sending it out into the body, according to a new study out of a University of North Carolina Lineberger ...

Can gene therapy be harnessed to fight the AIDS virus?

February 13, 2018
For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell's HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible.

Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018
Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.